senescence markers (p16 and p21)

Overview

Senescence markers p16 and p21 are widely used molecular indicators of cellular senescence, a stable growth-arrest program that accumulates in aging tissues and in response to stress, DNA damage, oncogenic signaling, and metabolic injury. p16 generally refers to p16^INK4a^, encoded by CDKN2A, while p21 refers to p21^Cip1/Waf1^, encoded by CDKN1A. Both proteins act as cyclin-dependent kinase inhibitors and help enforce cell-cycle arrest, particularly at the G1/S transition, making them central readouts in studies of aging, fibrosis, cancer biology, and tissue repair.

In biomedical research, p16 and p21 are often interpreted alongside other senescence- and damage-associated markers such as γH2AX, p53, Lamin B1, and SASP factors including IL-6, IL-1β, TNF-α, and matrix metalloproteinase-9. Their expression is frequently used to assess whether interventions alter senescence burden, cell-cycle progression, or stress responses in models involving reactive oxygen species, mitophagy, nuclear factor kappa B signaling, PTEN-related pathways, or DNA damage responses.

Focus of Latest Publications

Recent publications reveal context-dependent roles for the senescence markers p16 and p21 across multiple cancer types and age-related pathologies, with distinct therapeutic implications depending on disease and genetic background. Investigations into p21's role in cancer progression demonstrated bidirectional therapeutic opportunities: glucose transporter inhibition by MF48 activates the p53/p21/caspase-3 apoptotic cascade in colorectal cancer, while CNOT9 suppression in hepatocellular carcinoma increases p21 expression as part of PTEN/AKT/p53-mediated growth suppression. Conversely, in ARID1A-mutated tumors, p21 inhibition synergizes with WRN helicase blockade to overcome G1 arrest and induce mitotic catastrophe. CDKN2A loss, encompassing p16INK4a inactivation, proved essential for malignant transformation of neural crest progenitors in neurofibromatosis-associated peripheral nerve sheath tumors, establishing p16 as a critical tumor suppressor.

Beyond malignancy, p16 has emerged as a mechanistic driver of tissue senescence and fibrotic disease progression, making it an attractive therapeutic target for inhibition in age-related pathologies. Studies of idiopathic pulmonary fibrosis revealed elevated p16 expression strongly associated with autophagic dysfunction and matrix remodeling; genetic p16 depletion reduced fibrosis and restored autophagic flux independent of p21, while pharmacological p16 promoter inhibitors (toosendanin and abyssinone II) successfully attenuated bleomycin-induced pulmonary fibrosis in vivo. Age-related p16 upregulation specifically in ovarian somatic cells—cumulus, granulosa, and theca cells—correlated with declining reproductive function and reduced post-implantation outcomes during reproductive aging, whereas p16 did not increase in oocytes themselves. These findings establish p16 as a regulatory node between senescence and cellular dysfunction, with p16 inhibition offering therapeutic potential in aging and fibrotic contexts.

Complementary to p16 inhibition strategies, emerging therapeutic approaches have positioned p21 restoration as a tumor suppressor replacement strategy in malignancies where CDKN1A is inactivated or downregulated. Intravesical delivery of p21 mRNA encapsulated in lipid nanoparticles (p21-LNP) suppressed bladder cancer proliferation and promoted apoptosis through reduced retinoblastoma protein phosphorylation, decreased expression of cell cycle regulators (Cyclin E, Cyclin B, PCNA), and increased DNA damage marker accumulation (γ-H2A.X). In an orthotopic bladder cancer model, repeated p21-LNP administration significantly inhibited tumor growth and restored p21 expression in bladder tissue without overt systemic toxicity or disruption of normal urothelial architecture. Together, these findings underscore p16 and p21 as multivalent therapeutic targets: p16 inhibition restores tissue homeostasis through autophagy restoration in aging and fibrotic diseases, while p21 restoration provides direct tumor suppression in CDKN1A-inactivated cancers, and p21 inhibition enhances certain DNA damage-targeted therapies in specific genetic backgrounds such as ARID1A-mutated tumors.

Key Publications

• NEWJul CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. (Human cell, 2026, PMID 42384246): "CNOT9 knockdown activates PTEN to inhibit the AKT pathway and suppresses the expression of cell cycle-related proteins p53, p21, CCNE1 and CDK2."
• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42315971)
• NEWJun Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities. (Nature communications, 2026, PMID 42310314): "NF1-CDKN2A double-knockout (2KO) NCs form neurofibroma-like tumors in vivo, requiring inactivation of p14ARF and p16INK4a."
• NEWJun Targeting the senescence‒autophagy axis via p16INK4a inhibition alleviates pulmonary fibrosis. (Signal transduction and targeted therapy, 2026, PMID 42297772): "...independent of p21Cip1."
• Jun Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers. (Science advances, 2026, PMID 42247504): "Additional p21 inhibition in the context of WRN suppression promoted cell cycle reentry of G1-arrested ARID1A-mutated cells, resulting in enhanced cytotoxicity through mitotic catastrophe."
• May Adverse outcome pathway-based analysis of vanillic acid-induced neurodevelopmental toxicity and cellular senescence in zebrafish. (Ecotoxicology and environmental safety, 2026, PMID 42161108): "At the molecular level, VA exposure affected the expression of multiple key genes involved in nervous system, sensory organ development and cellular senescence, such as gfap, pomca, bdnf, s100b, insm1a, mbpa, p21, and telom."
• Jun Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. (Developmental cell, 2026, PMID 42161274): "We demonstrate that CDKN2A loss, which is nearly universal in patients but dispensable in mouse models, is essential for neoplastic transformation when combined with KRAS and TP53 mutations, whereas SMAD4 loss promotes tumor progression."
• Jun Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42144924): "Among tumor suppressors altered in bladder cancer, CDKN1A, which encodes the cyclin-dependent kinase inhibitor p21, is recurrently inactivated and downregulated, supporting its potential as a target for tumor suppressor replacement."
• May Age-related upregulation of p16 expression in mouse ovarian somatic cells correlated with reproductive function decline p16 expression and ovarian aging in mice. (PloS one, 2026, PMID 42101984): "Cellular senescence, marked by p16, contributes to age-related tissue dysfunction."